Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.
OBJECTIVE
The aim of this study is to define the maximal safe radiation dose to guide further study of the GliaSite balloon brachytherapy (GSBT) system in untreated newly diagnosed glioblastoma (NEW-GBM) and recurrent high-grade glioma (REC-HGG). GBST is a balloon placed in the resection cavity and later filled through a subcutaneous port with liquid I-125 Iotrex, providing radiation doses that diminish uniformly with distance from the balloon surface.


METHODS
The Adult Brain Tumor Consortium initiated prospective dose-finding studies to determine maximum tolerated dose in NEW-GBM treated before standard RT or after surgery for REC-HGG. Patients were inevaluable if there was progression before the 90-day posttreatment toxicity evaluation point.


RESULTS
Ten NEW-GBM patients had the balloon placed, and 2/10 reached the 90 day timepoint. Five REC-HGG enrolled and two were assessable at the 90-day evaluation endpoint. Imaging progression occurred before 90-day evaluation in 7/12 treated patients. The trials were closed as too few patients were assessable to allow dose escalation, although no dose-limiting toxicities (DLTs) were observed. Median survival from treatment was 15.3 months (95 % CI 7.1-23.6) for NEW-GBM and 12.8 months (95 % CI 4.2-20.9) for REC-HGG.


CONCLUSIONS
These trials failed to determine a maximum tolerated dose (MTD) for further testing as early imaging changes, presumed to be progression, were common and interfered with the assessment of treatment-related toxicity. The survival outcomes in these and other related studies, although based on small populations, suggest that GSBT may be worthy of further study using clinical and survival endpoints, rather than standard imaging results. The implications for local therapy development are discussed.
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Cancer Center, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA.
L R
LR
Kleinberg
Piedmont Radiation Oncology, Winston-Salem, NC, USA.
V
V
Stieber
Henry Ford Hospital, Detroit, MI, USA.
T
T
Mikkelsen
Thomas Jefferson University Hospital, Philadelphia, PA, USA.
K
K
Judy
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Cancer Center, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA.
J
J
Weingart
Cleveland Clinic, Cleveland, OH, USA.
G
G
Barnett
Emory University, Atlanta, USA.
J
J
Olson
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Cancer Center, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA.
S
S
Desideri
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Cancer Center, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA.
X
X
Ye
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Cancer Center, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA.
S
S
Grossman
Brachytherapy; Glioblastoma; Glioma; I-125; Radiotherapy
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1385-91
19394153
J Clin Oncol. 2002 Mar 15;20(6):1635-42
11896114
Curr Treat Options Oncol. 2011 Sep;12(3):240-52
21594589
J Clin Oncol. 2003 May 1;21(9):1845-9
12721262
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8
16750317
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):421-9
9788425
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88
9989517
Cancer Biother Radiopharm. 2000 Dec;15(6):645-56
11190496
Future Oncol. 2014 May;10(7):1277-97
24947265
Cancer Invest. 2004;22(1):1-9
15069758
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11
9719109
Neuro Oncol. 2003 Apr;5(2):79-88
12672279
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
2542195
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):159-65
17331666
J Neurooncol. 2011 Jan;101(2):319-23
21052776
J Neurosurg. 2002 Feb;96(2):335-43
11838809
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1167-76
7607939
Tumori. 2011 Sep-Oct;97(5):614-9
22158493
Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
16482400
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9
15990019
J Neurooncol. 1995 Nov;26(2):111-23
8787853
J Neurosurg. 2003 Aug;99(2):297-303
12924704
Neuro Oncol. 2008 Jun;10(3):361-7
18401015
AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):1885-92
21920854
Lancet Oncol. 2008 May;9(5):453-61
18452856
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60
15465203
Neurosurgery. 2006 Apr;58(4):701-9; discussion 701-9
16575334
J Neurosurg. 1991 Mar;74(3):441-6
1993909
AJNR Am J Neuroradiol. 2004 Aug;25(7):1211-7
15313712
Lancet. 1995 Apr 22;345(8956):1008-12
7723496